Erasca (ERAS) Investor Presentation - Slideshow

Erasca's Pipeline and Strategy - Erasca is focused on shutting down the RAS/MAPK pathway to address unmet needs in over 5 million patients globally[120] - The company's pipeline targets every node of the RAS/MAPK pathway with multiple clinical-stage compounds[227] - Erasca's strategy involves targeting upstream and downstream RAS/MAPK nodes, clamping oncogenic drivers, and targeting escape routes[238] Naporafenib (Pan-RAF Inhibitor) - Naporafenib, combined with trametinib, demonstrated a 46.7% ORR and 80% DCR in a Phase 1 study for NRASm melanoma[256] - In a Phase 2 study, naporafenib with trametinib showed a 25% ORR and 70.8% DCR in NRASm melanoma[256] - Naporafenib has been dosed in more than 500 patients to date, establishing its safety and tolerability[263] ERAS-007 (ERK1/2 Inhibitor) and ERAS-601 (SHP2 Inhibitor) - A study showed that 23% (6 out of 26) of patients with RAS/MAPK-altered non-CRC solid tumors responded to single-agent ERAS-007 or ERAS-601[130, 143] - ERAS-007 has a longer target residence time compared to other ERKi's, potentially allowing for longer intervals between doses[284] - ERAS-601 demonstrated significant tumor inhibition when combined with cetuximab in triple wildtype CRC and HPV-negative HNSCC models[287] ERAS-801 (CNS-Penetrant EGFR Inhibitor) - ERAS-801 is designed to inhibit EGFR in Glioblastoma Multiforme (GBM), addressing a high unmet need in 37,000 patients in the US and EU[67, 84] - ERAS-801 has a Kp,uu (brain) of 1.2, which is over 4-fold higher than approved EGFR inhibitors[88]